In the contemporary treatment of HF, apart from the inhibition of the renin–angiotensin–aldosterone axis as a mode of action of other major heart failure drug classes, SGLT2is have consistently shown cardiovascular benefits, likely through various mechanisms, including direct metabolic effects on the myocardium, vessels and kidneys [18]. The gene discussed is REN; the disease is heart failure.